- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
- Interventions
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 71 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2030
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 11,403
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma, Diffuse Glioma
- Interventions
- NMS-03305293, Temozolomide
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Orange, California • Jacksonville, Florida + 8 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- T Cell Proliferation and Autoreactivity Assays, Cellular Immunoblot Assays, Tetramer Studies, Cytokine ELISPOT
- Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 35 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 10 more
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- Etravirine, Ritonavir, Darunavir
- Drug
- Lead sponsor
- Tibotec, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 22
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Out-Of-Hospital Cardiac Arrest
- Interventions
- igel, Compression Rate
- Device · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Severe Hemophilia A
- Interventions
- rFVIIIFc
- Biological
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Salt Lake City, Utah • Seattle, Washington
- Conditions
- Glycogen Storage Disease Type II, Pompe Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2034
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Tofacitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 43
- States / cities
- Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 23 more
- Conditions
- Pregnancy
- Interventions
- Not listed
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Stanford, California • Seattle, Washington
- Conditions
- Down Syndrome, Chromosome Abnormalities
- Interventions
- Ultrasound, Serum screen
- Procedure
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 16 Years to 45 Years · Female only
- Enrollment
- 38,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Boston, Massachusetts • Royal Oak, Michigan + 6 more
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
- Interventions
- daraxonrasib, gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
- Conditions
- Menopause
- Interventions
- esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 35 Years to 65 Years · Female only
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 78
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more
- Conditions
- Contraception
- Interventions
- Testosterone Enanthate, Dutasteride, placebo sesame oil
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
- Interventions
- bortezomib, rituximab, laboratory biomarker analysis, immunohistochemistry staining method, RNA analysis, gene expression analysis, DNA analysis, pharmacological study, pharmacogenomic studies, Questionnaire Administration
- Drug · Biological · Other + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 2
- States / cities
- Duarte, California • Seattle, Washington
- Conditions
- Cleft Palate, Cleft Lip and Palate
- Interventions
- Book-Sharing for Toddlers with Clefts (BOOST)
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 20 Months to 32 Months
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer
- Interventions
- Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
- Device
- Lead sponsor
- U-Systems, Inc.
- Industry
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 15,679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Indio, California • Monterey, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Atrial Septal Defect Secundum
- Interventions
- atrial septal occluder
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 50 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- Placebo, RO5285119
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 45
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Orange, California + 41 more
- Conditions
- Wounds
- Interventions
- After-care summary, Control group
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Seattle, Washington
- Conditions
- Aging, Mild Cognitive Impairment
- Interventions
- TH9507 human growth hormone releasing hormone (GHRH)
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Solid Tumors That Overexpress HER2 (HER2 Positive)
- Interventions
- FS102
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Memphis, Tennessee + 2 more
- Conditions
- Sleep Apnea, Obstructive, Stroke, Patient Adherence
- Interventions
- Continuous Positive Airway Pressure
- Device
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 9
- States / cities
- New York, New York • Greenville, North Carolina • Fargo, North Dakota + 3 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Concurrent temozolomide, Concurrent radiation therapy, 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle, 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1,173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 341
- States / cities
- Fairbanks, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 240 more